Trial
NCT01431794
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Novartis Pharmaceuticals; The Skip Viragh Foundation
Condition
Pancreatic Ductal Adenocarcinoma
Intervention
LDE225-600mg
Why stopped
Study was terminated due to cease in manufacturing of study drug.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-01-22